QbD, Antleron, Inovigate, Eye-Tec, Neuroplast and Anicells would like to invite you to their event on Advanced & Breakthrough therapies. By means of different keynotes that afternoon, they intend to highlight the different aspects of the ATMP-lifecycle.
The afternoon will be ended with a panel discussion about "innovating end-to-end to win, from a single therapy and for the region". The panel will exist of Philippe De Backer, Pascale Engelen (Flanders.bio), Annie Hubert (Alliance for Regenerative Medicine) and David Callaert (Novartis).
12.00h Welcome + lunch
13.00h Introduction – Bart Van Acker, CEO QbD
13.15h “GMP for ATMP: one year into the new part IV” – Bram Keymolen, co-founder Eye-Tec
14.00h “Innovative technologies fueling personalized cell therapy” – Jan Schrooten, CEO Antleron
15.15h “Challenges in scaling and control strategy from lab to patient” – Nicolas Theys, Chief Operating Officer Novadip
16.00h “Lessons learned from the cell therapy trials. Time for a new approach?” – Jean-Paul Deslypere, CEO Aesculape
16.45h “Innovative Funding solutions for breakthrough therapies” – Ingrid Maes, Managing Director Inovigate BE
17.15h Panel discussion – “Innovating end-to-end to win, from a single therapy and for the region”
- Philippe De Backer
- Pascale Engelen, CO Managing Director Flanders.bio
- Annie Hubert, Senior Director Alliance for Regenerative Medicine
- David Callaert, Head of Engineering Global BTDM at Novartis
18.15h Network Reception
Living Tomorrow Brussels
1 Indringingsweg, 1800 Vilvorde
QbD, Antleron, Anicells, Neuroplast, Eye-Tec en Inovigate.